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Abstract Okadaic acid is an inhibitor of the protein Ser/Thr
phosphatases PP1 and PP2A, which blocks the activation of
extracellular signal-regulated protein kinase 5 (ERK5), a mem-
ber of the MAP kinase family activated by growth factors and
several types of stressors. The blocking of ERK5 activation by
okadaic acid was observed in HeLa cells exposed to epidermal
growth factor and H2O2 as well as in PC12 cells stimulated by
nerve growth factor and H2O2. Calyculin A, another PP1 and
PP2A inhibitor, behaved similarly although these compounds
are not structurally related. This suggests that either PP1 or
PP2A or both are necessary for ERK5 activation. Protein ki-
nase C (PKC) acts as a negative regulator of the ERK5 acti-
vation pathway, however our data suggest that the e¡ects of
PKC and the phosphatase are unrelated. . 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Mitogen activated protein kinase (MAPK) cascades are or-
ganised in modules that contain three protein kinases acti-
vated by sequential phosphorylations. MAP kinases are acti-
vated by dual-speci¢city kinases [MAPK/extracellular signal-
regulated protein kinases (ERK) or MEK] which in turn are
activated by phosphorylation in Ser/Thr residues by MEK
kinases. ERK5 is a member of the MAPK family which is
activated in response to mitogens and several types of stress
[1,2]. ERK5 activation requires dual phosphorylation in a
TEY motif, which makes this kinase more similar to ERK1/
2 than to the other members of the MAPK family. However
ERK5 has a unique C-terminal sequence that is not present in
other members of the family [3,4]. The role of ras in ERK5
activation seems to be cell dependent. In HeLa cells the over-
expression of mutant forms of ras have no e¡ect on ERK5
activation by epidermal growth factor (EGF) [1], whereas in
rat pheochromocytoma cell line (PC12) and COS7 cells the
activation of ERK5 by EGF and nerve growth factor (NGF)
seems to be ras dependent [5].
MEK5 has been reported to be the only kinase able to
activate ERK5 and experiments using dominant negative
forms of MEK5 suggest that this kinase is selective for the
ERK5 pathway [1]. Raf, mos and MEKK1, speci¢c MEK
kinases of the ERK and JNK pathways, are unable to activate
MEK5 [6]. In contrast, MEKK2 [7], MEKK3 [8] and the cot
oncoprotein [9] activate ERK5 in a MEK5 dependent manner,
and experiments using a dominant negative mutant of
MEKK3 suggest that in some cell types this kinase is a medi-
ator of EGF and H2O2 activation of ERK5 [7,8]. A role for
c-src in H2O2 mediated ERK5 activation has also been de-
scribed [10]. In contrast to the positive e¡ect of these protein
kinases, protein kinase C (PKC) has been described as a neg-
ative regulator of ERK5 activation [11].
The function of protein phosphatases in the regulation of
MAP kinase pathways has been mainly associated to the
down-regulation of these pathways. The dual-speci¢city phos-
phatases are responsible for selective dephosphorylation of
the critical phosphothreonine and phosphotyrosine residues
present in the di¡erent members of the MAP kinase family.
However PP2A and a uncharacterised tyrosine phosphatase
have been involved in the early inactivation of EGF stimu-
lated MAP kinase in PC12 cells [12]. Moreover PP2A can act
at multiple levels of the cascade, as suggested by the observa-
tions that this enzyme can dephosphorylate MEK1/2 in vitro
[13] and that this kinase is activated by the treatment of cells
with okadaic acid [14]. In this paper we describe the e¡ect of
okadaic acid and calyculin A, two Ser/Thr phosphatase inhib-
itors speci¢c for protein phosphatase 1 (PP1) and protein
phosphatase 2A (PP2A), on the ERK5 pathway. Our results
show that, opposite to what is observed in other MAP kinase
pathways, ERK5 activation requires the activity of a PP1/
PP2A-like phosphatase to become activated.
2. Materials and methods
2.1. Reagents and antibodies
NGF and EGF were purchased from Life Technologies. Okadaic
acid, calyculin A, cyclosporine A, GF109203X and U0126 were from
Calbiochem. Anti ERK5 (C-20) (1/100) was from Santa Cruz, anti-
p42 ERK2 (1 Wg/ml) from Upstate Biotech, anti-phospho ERK5
(3 Wg/ml) from Calbiochem and anti phospho-MAPK (1/2000) from
New England Biolabs. Enhanced chemiluminescence reagent (ECL),
protein G-Sepharose and [Q-32P]ATP were from Amersham-Pharma-
cia. Tissue culture reagents were from Gibco.
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2.2. Cell culture and preparation of lysates
HeLa cells were cultured at 37‡C in a 95/5 air/CO2 water saturated
atmosphere in Dulbecco’s modi¢ed Eagle’s medium (DMEM) con-
taining 10% heat inactivated foetal bovine serum (FBS) and PC12
cells in DMEM containing 10% heat inactivated horse serum, 5%
heat inactivated FBS, both containing 2 mM L-glutamine, 100 U/ml
penicillin and 100 Wg/ml streptomycin. For treatments, the cells were
transferred to 60 mm dishes and after 48 h starved overnight in
DMEM. The cells were incubated with the inhibitors for the indicated
times and then stimulated with EGF (100 ng/ml), NGF (50 ng/ml) or
H2O2 (1 mM). Cells were harvested, washed with cold phosphate-
bu¡ered saline and lysed with 0.2 ml of bu¡er A (50 mM Tris/HCl,
pH 7.5, 0.27 M sucrose, 1 mM EGTA, 1 mM EDTA, 50 mM NaF,
1 mM sodium orthovanadate, 10 mM sodium L-glycerophosphate,
5 mM PPi, 1% Triton X-100, 1 mM benzamidine, 1 mM phenylmeth-
ylsulfonyl£uoride (PMSF), and 0.1% (v/v) L-mercaptoethanol). After
15 min on ice the lysate was removed from the dishes and centrifuged
at 13 000Ug for 15 min at 4‡C. Supernatants were used for Western
blotting and kinase assays.
2.3. Immune complex ERK5 kinase assay
To assay ERK5 activity, 5 Wl of protein G-Sepharose equilibrated
in bu¡er A were incubated with 5 Wg of anti ERK5 during 30 min at
4‡C. The beads were washed twice with bu¡er A and 500 Wg of cell
extract protein was added and incubated for 90 min at 4‡C. The
immunocomplexes were washed twice with bu¡er A plus 0.5 M
NaCl and twice with kinase assay bu¡er (50 mM Tris^HCl pH 7.5,
0.1 mM EGTA, 0.1% L-mercaptoethanol).
The assay was done at 30‡C for 30 min in a 50 Wl ¢nal volume of
kinase assay bu¡er containing 0.1 mM ATP (5 WCi per assay), 5 mM
Mg acetate and 0,33 mg/ml of myelin basic protein (MBP) as sub-
strate. Reaction was stopped with Laemmli sample bu¡er and pro-
teins separated by sodium dodecyl sulphate^polyacrylamide gel elec-
trophoresis (SDS^PAGE) in a 12% gel and the corresponding band
detected by autoradiography and quanti¢ed by densitometry.
2.4. Western blot analysis
The protein content of cellular extracts was quanti¢ed by Bradford
assay [15]. For ERK5 band-shift assay 100 Wg of protein were loaded
on 7% SDS^PAGE. For ERK1/2, 50 Wg of protein were loaded in
10% gels. To detect phospho-ERK5, 500 Wg of cell extracts were
immunoprecipitated as described above and separated in a 10% gel.
The proteins were transferred onto PVDF membranes and incubated
with the corresponding antibodies at the indicated concentrations.
Proteins were detected using the ECL.
3. Results
3.1. PKC and classical phosphatases PP1/PP2A inhibitors do
not cooperate on ERK5 activation
PKC has been described as a negative regulator of ERK5
activation in response to G-CSF [11]. In agreement with this
notion we observed that preincubation of HeLa and PC12
cells with the PKC inhibitor GF109203X potentiated the ac-
tivation of ERK5 by EGF and NGF respectively, as mea-
sured as a shift in the mobility of ERK5 in SDS^PAGE
(Fig. 1).
We asked the possibility that a protein phosphatase would
reverse the e¡ects of PKC, and as a ¢rst approach we decided
to test the possible involvement of a PP1- or PP2A-like phos-
phatase. We reasoned that if PKC and one of these phospha-
tases had the same target, combinatorial treatments of the
Fig. 1. E¡ect of some kinase and phosphatase inhibitors on ERK5 activation. HeLa and PC12 cells were starved overnight and then incubated
for 30 min with 10 WM U0126 (U0126), 1 WM okadaic acid (OA, OA/GF) or 5 WM GF109203X (GF, GF/OA). In OA/GF and GF/OA, 5 WM
GF109203X and 1 WM okadaic acid were added respectively after the ¢rst treatment, and the cells were further incubated for 30 min. Finally
the cells were stimulated with 100 ng/ml EGF for 15 min (A) or 50 ng/ml NGF for 30 min (B). ERK5 activation was detected as a shift in its
mobility. ERK1/2 phosphorylation was detected using an antibody against their dual phosphorylated forms. In order to check that the same
amount of protein was loaded an antibody against p42-ERK2 was used.
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cells with GF109203X and okadaic acid might lead to di¡er-
ent phosphorylation levels of their target, what would in£u-
ence the strength of ERK5 activation by growth factors. Un-
expectedly, treatment with okadaic acid either prior to or after
the addition of GF109203X resulted in a blockage in ERK5
activation by growth factors. The previous data could be con-
sidered as indicative that a PP1- or PP2A-type phosphatase
acted as a positive regulator of the ERK5 pathway activation
in response to EGF or NGF, what would be in contrast with
that described for the ERK1/2 pathway. In fact, treatment of
the cells with okadaic acid alone blocked ERK5 activation in
a way similar to U0126, a compound shown to block ERK5
as well as ERK1/2 activation. No e¡ects of okadaic acid or
GF 109203X were observed on ERK1/2 phosphorylation.
3.2. Protein phoshatases PP1 and PP2A inhibitors block the
EGF stimulated ERK5 activation in HeLa cells
In HeLa cells, we observed that EGF-promoted ERK1/2
phosphorylation reached a maximum at 5 min and was po-
tentiated by inhibition of phosphatases with okadaic acid. In
these experiments, EGF also stimulated ERK5 reaching a
maximal activation at 15 min (Fig. 2). The e¡ect of okadaic
acid on ERK5 was a blockage of the activation, measured
either as a shift in ERK5 mobility, with antibodies against
phosphorylated ERK5 or by direct assay of its activity on
MBP. To check if the e¡ect of okadaic acid on ERK5 acti-
vation was unspeci¢c, we performed similar experiments using
calyculin A, another protein phosphatase inhibitor speci¢c for
PP1 and PP2A but with a completely di¡erent chemical struc-
ture. Both inhibitors blocked the activation of ERK5 in a
concentration dependent manner (Fig. 3A^C), but they did
not block ERK1/2 phosphorylation. In contrast to this, treat-
ment of the cells with 4 WM cyclosporine A, a potent inhibitor
of PP2B did not block ERK1/2 or ERK5 activation in re-
sponse to EGF in HeLa cells (Fig. 3C).
3.3. Okadaic acid and calyculin A also block ERK5 activation
in response to oxidative stress
In addition to its response to EGF and NGF, ERK5 path-
way is also activated by some stressors, what distinguishes it
from the ERK1/2 pathway. To check if okadaic acid also
a¡ected ERK5 activation by other stimulus, HeLa and
PC12 cells were stimulated with H2O2 either directly or after
pretreatment with okadaic acid or with calyculin A (Fig. 4). In
both cell types activation of ERK5 was inhibited by these
phosphatase inhibitors.
4. Discussion
The function of protein phosphatases on MAP kinase path-
ways has been mainly associated to their down-regulation.
Dual-speci¢city phosphatases act directly on MAP kinases
and cause their inactivation, whereas the classical Ser/Thr
phosphatases may also act on di¡erent components located
upstream in the activation cascade. Keeping this in mind, it
was unexpected to observe that inhibition of the classical PP1/
Fig. 2. EGF stimulated ERK5 activation in HeLa cells is blocked by okadaic acid. HeLa cells were serum starved overnight, treated with 1 WM
okadaic acid (OA) or DMSO for 30 min, and then stimulated with 100 ng/ml EGF for the indicated times. Cells were lysed and the extracts
processed as indicated under materials and methods. ERK5 activation was detected as (A) a shift in its mobility or with speci¢c antibodies
against the phosphorylated form of the enzyme, and (B) by its activity in an immunocomplex kinase assay. ERK1/2 phosphorylation was de-
tected using an antibody against their dual phosphorylated forms. In order to check that the same amount of protein was loaded an antibody
against p42-ERK2 was used.
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PP2A phosphatases with okadaic acid completely blocked the
activation of ERK5 instead of potentiating its activation, as
occurs with ERK1/2. It must be emphasized that the e¡ect of
okadaic acid on other MAP kinase pathways has always been
an increase in MAP kinase activation [14,16]. Interestingly,
calyculin A mimicked okadaic acid e¡ects on ERK5 activa-
tion and the e¡ects of both compounds were concentration
dependent in a range that agrees with their potencies as phos-
phatase inhibitors. This argues against an unspeci¢c e¡ect of
okadaic acid and reinforces the idea that a PP1- or PP2A-type
phosphatase must be involved.
The e¡ects of okadaic acid and calyculin A on ERK5 were
not restricted to its stimulation by growth factors but were
also observed in its response to oxidative stress. Although it is
known that calyculin A shows the same speci¢city for PP1
and PP2A whereas okadaic acid is a better inhibitor of
PP2A than of PP1, our experiments in vivo do not allow to
discriminate between these two phosphatases. Nevertheless,
our results indicate that a PP1/PP2A-like phosphatase activity
is mandatory for ERK5 to become activated in response to
several stimuli.
It is known that PKC negatively regulates the activation of
ERK5 [11]. The possibility that PKC and the phosphatase
involved in ERK5 activation targeted the same component
of the activation cascade is not supported by our results on
the combinatorial e¡ects of the inhibitors. It is worth noting
that the e¡ect of okadaic acid blocking ERK5 activation al-
ways prevailed over that of GF109203X, what could be inter-
preted as a prominent role of the PP1/PP2A-type phosphatase
on the regulation of ERK5 pathway.
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